H. Lundbeck A/S' Compound for the Treatment of Anxiety Disorder - Seramesine - Enters Clinical Phase II Release No 26 COPENHAGEN, Denmark, August 14, 2000 (PRIMEZONE) -- H. Lundbeck A/S hereby announces that seramesine has just initiated clinical phase II studies. Seramesine is a compound for the treatment of...